- THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Since a thienopyridine derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof of the present invention has an excellent effect of inhibiting protein kinase activity, a pharmaceutical composition comprising the same can be usefully used for preventing or treating diseases related to protein kinase activity.COPYRIGHT KIPO 2020
- -
-
Paragraph 0241; 0242-0245
(2019/10/29)
-
- THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions comprising same can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.
- -
-
Page/Page column 31-32
(2019/10/15)
-
- PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS
-
There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.
- -
-
Paragraph 00203-00204; 00253-00254
(2016/04/09)
-
- Process for the preparation of fused pyridine compounds
-
2-Amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-en-1-yl]pyrido[2,3,-d]pyrimidines and 2-amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-yn-1-yl]pyrido[2,3-d]pyrimidines are prepared through the reaction of a haloaromatic compound and an unsaturated compound in the presence of a palladium catalyst. The products are chemical intermediates for the preparation of antineoplastic agents. A typical embodiment is the reaction of a protected 2-amino-4-hydroxy-6-ethynylpyrido[2,3-d]pyrimidine and an ester of 4-iodobenzoic acid.
- -
-
-